According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

The ELEVATUM study's initial data showed vision improvements in patients who were given Vabysmo every eight weeks for a year.

Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over ... Since AMD is closely linked with aging, some researchers have turned their attention to ...

Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over 50 in the United States.

A study published in Nature Medicine suggests a new experimental drug could someday help make ... a novel synthetic protein to treat macular degeneration and other incurable eye diseases that ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

This growth in the Age-Related Macular Degeneration market is fueled by ... in research and development investments that lead to more drug approvals and improved reimbursement policies.

Our latest Mane Attraction spawned some interesting replies from both sides of the aisle…but not what the “both sides” anticipated.